Interstitial fibrosis is the buildup of scar tissue in the spaces between the functional cells of an organ, gradually replacing healthy tissue with stiff, collagen-heavy material that impairs normal function. It most commonly refers to the lungs, where it falls under the umbrella of interstitial lung diseases, but the same scarring process affects the kidneys, heart, and liver. The underlying biology is remarkably similar across organs: cells called myofibroblasts deposit excess structural proteins in response to injury signals that fail to shut off properly. What makes interstitial fibrosis particularly concerning is that by the time symptoms appear, significant scarring has usually already taken hold, and in many cases the damage cannot be fully reversed.
How the Scarring Process Works
When tissue is injured, the body launches a repair response. Immune cells rush to the site, clean up damaged material, and signal local cells to patch the wound with collagen and other structural proteins. In a healthy repair cycle, this process winds down once the wound closes. In interstitial fibrosis, it doesn’t. Fibroblasts, the cells responsible for laying down structural scaffolding, transform into myofibroblasts under stimulation from signaling molecules released by immune cells, damaged tissue, and even small vesicles shed by nearby cells. Myofibroblasts are repair cells stuck in overdrive: they produce far more collagen, fibronectin, and other structural proteins than the tissue needs, and they resist the normal signals telling them to stop or self-destruct.
In the lungs, this process is well characterized in idiopathic pulmonary fibrosis, a progressive and ultimately fatal condition. Repeated cycles of injury and abnormal repair lead to the gradual replacement of normal lung architecture with dense fibrous tissue.1PubMed Central. Mechanisms and Therapeutic Potential of Myofibroblast Transformation in Pulmonary Fibrosis In the kidneys, the same pattern plays out in the tissue surrounding the tubules. Studies in chronic kidney disease show that myofibroblasts accumulate alongside abnormal deposits of collagen types I and III, fibronectin, and tenascin, and that the amount of scar tissue tracks with the severity of kidney damage.2PubMed. Macrophages, myofibroblasts, and extracellular matrix accumulation in interstitial fibrosis of chronic progressive nephropathy in aged rats In the heart, interstitial fibrosis shows up as a diffuse web of excess collagen between muscle fibers, stiffening the walls and eventually contributing to heart failure.3PubMed Central. Myocardial Interstitial Fibrosis in Nonischemic Heart Disease, Part 3/4: JACC Focus Seminar
Causes in the Lungs
Pulmonary interstitial fibrosis has many potential triggers, and often more than one is at play. The causes fall into several broad categories, and in a frustrating number of cases no cause can be identified at all, which is what makes a diagnosis “idiopathic.”
Environmental and Occupational Exposures
Inhaling certain dusts and fumes over months or years is one of the clearest risk factors. Case-control studies have linked cigarette smoke, wood dust, metal dust, sand and silica, and agricultural exposures to increased risk of developing pulmonary fibrosis.4PubMed Central. Asbestosis and environmental causes of usual interstitial pneumonia Asbestos is the most well-known culprit, but it is far from the only one. Cumulative lifetime exposures interact with genetic susceptibility and affect multiple pathways, including the lung’s microbial communities. Cigarette smoke, silica, and air pollution all alter the respiratory microbiome, which can in turn influence immune responses and scar-forming pathways.5PubMed. Molecular mechanisms of environmental risk factors for interstitial lung disease
Autoimmune and Connective Tissue Diseases
Many autoimmune conditions attack connective tissue throughout the body, and the lungs are especially vulnerable because they are packed with collagen and blood vessels. Connective tissue disease-related interstitial lung disease is one of the leading causes of serious illness and death in people with conditions like rheumatoid arthritis, lupus, and scleroderma.6PubMed Central. Interstitial Lung Disease in Connective Tissue Disease: A Common Lesion With Heterogeneous Mechanisms and Treatment Considerations In systemic sclerosis (scleroderma), interstitial lung disease is considered one of the two leading causes of death among patients. The mechanism involves a combination of blood vessel damage, immune system misfiring, and chronic inflammation.7PubMed. Pathogenesis and therapeutics of interstitial lung disease in systemic sclerosis
Medications
A surprising number of drugs can damage the lung interstitium. Chemotherapy agents, certain antibiotics, heart rhythm medications, and even some immunosuppressive drugs have been associated with drug-induced interstitial lung disease, producing inflammation and fibrosis.8PubMed Central. Drug induced interstitial lung disease Bleomycin, a chemotherapy drug used to treat some cancers and lymphomas, is probably the most notorious. It is so reliably fibrosis-inducing that researchers use it in the lab to create animal models of pulmonary fibrosis.9Pakistan Journal of Pharmaceutical Sciences. Effect Of Peimisine On Pulmonary Interstitial Fibrosis Induced By Bleomycin In Mouse Pulmonary Fibrosis Drug-induced cases can sometimes improve once the offending medication is stopped, which makes early recognition critical.
Infections, Including COVID-19
Severe lung infections can trigger fibrotic scarring during the healing process. This concern gained new urgency during the pandemic: post-COVID pulmonary fibrosis emerged as a major complication among survivors of severe disease. The severity of the initial respiratory illness, especially when it progressed to acute respiratory distress syndrome, is the strongest documented risk factor. About a quarter of ARDS survivors end up with evidence of fibrotic changes and restricted lung function afterward.10European Respiratory Review. Scars from the pandemic: understanding post-COVID-19 interstitial lung disease Older age, male sex, and the overall severity of the COVID illness also raise the risk.11PubMed Central. Post-COVID-19 pulmonary fibrosis: An ongoing concern
Genetic and Idiopathic Factors
Even when there is no clear environmental trigger, genetics play a real role. The strongest known genetic risk factor for pulmonary fibrosis is a variant in the MUC5B gene’s promoter region. People who carry one copy of this variant have roughly 2.8 times the odds of developing interstitial lung abnormalities and over 6 times the odds of definite pulmonary fibrosis on imaging.12PubMed Central. MUC5B promoter polymorphism and interstitial lung abnormalities Together with other common genetic variants, MUC5B explains roughly a third of the overall disease risk for idiopathic pulmonary fibrosis.13PubMed Central. MUC5B and Idiopathic Pulmonary Fibrosis The same MUC5B variant also appears in autoimmune-related fibrosis; in rheumatoid arthritis patients, carrying the variant roughly doubled the odds of developing interstitial lung disease.14PubMed Central. Genetic, social, and environmental risk factors in rheumatoid arthritis-associated interstitial lung disease Other genetic contributions include mutations in surfactant protein genes, abnormalities in telomere length and telomerase activity, and aberrant signaling from growth factors and cytokines.15PubMed Central. Determinants of initiation and progression of idiopathic pulmonary fibrosis
When Fibrosis Affects the Kidneys and Heart
Interstitial fibrosis is not a lung-exclusive problem. In the kidneys, the scarring of tissue between the tubules, often described as interstitial fibrosis and tubular atrophy, is essentially the final common pathway for most forms of chronic kidney disease regardless of the original cause. Whether the initial insult was diabetes, high blood pressure, autoimmune nephritis, or a transplant slowly failing, the end result is fibroblasts and myofibroblasts depositing excess collagen in the interstitium. Multiple molecular signaling pathways are involved, and assessment of this scarring on biopsy is central to grading how far chronic kidney disease has progressed.16PubMed Central. Renal interstitial fibrosis: mechanisms and evaluation
In the heart, myocardial interstitial fibrosis stiffens the muscle walls, impairs the heart’s ability to relax and fill with blood, and is associated with progression to heart failure. Unlike a discrete scar from a heart attack, interstitial fibrosis is diffuse, spreading through the tissue as a network of thickened collagen strands and tiny scars. The excess collagen is not just quantitatively different from normal but qualitatively altered, with changes in the cross-linking between fibers that make the tissue stiffer than even its volume would predict.3PubMed Central. Myocardial Interstitial Fibrosis in Nonischemic Heart Disease, Part 3/4: JACC Focus Seminar This type of fibrosis contributes to left ventricular dysfunction and is a hallmark of several cardiac diseases.17PubMed. Myocardial Interstitial Fibrosis in Heart Failure: Biological and Translational Perspectives
How It Is Diagnosed
In the lungs, the diagnostic process usually starts with symptoms: a persistent dry cough and worsening shortness of breath, especially during activity. A high-resolution CT scan of the chest is the primary imaging tool. It reveals characteristic patterns that help clinicians distinguish between different types of fibrosis. In one study of rheumatoid arthritis patients, the most common CT findings were thickening of the walls between lung segments, ground-glass haziness, and honeycomb-like cysts concentrated in the lower parts of the lungs.18PubMed Central. Rheumatoid Arthritis Related Interstitial Lung Disease: Patterns of High-resolution Computed Tomography These findings help classify the pattern as either usual interstitial pneumonia (the pattern seen in idiopathic pulmonary fibrosis) or nonspecific interstitial pneumonia (more common in autoimmune-related disease), among other subtypes.
When imaging is ambiguous, lung biopsy still plays a valuable role. Histopathologic evaluation in uncertain cases has been shown to change the treatment approach in roughly a third of patients, shifting management away from a cautious “wait and see” strategy and toward timely use of antifibrotic drugs or immunosuppressive therapy.19CHEST. Should Surgical Lung Biopsy Still Be Performed for Interstitial Lung Disease Evaluation? Yes For kidney and heart fibrosis, tissue biopsies and advanced cardiac MRI techniques, respectively, remain the gold standards.
How Common Is It
Interstitial lung disease as a whole is not rare but is underrecognized. A systematic review looking across seventeen studies from multiple continents found that the incidence ranged from about 1 to 31.5 new cases per 100,000 people per year, and prevalence ranged from about 6 to 71 per 100,000. In North America and Europe, idiopathic pulmonary fibrosis and sarcoidosis were the most common subtypes. The proportion of cases linked to connective tissue diseases showed striking geographic variability, ranging from less than 8% in some European cohorts to over a third in some Middle Eastern and Canadian cohorts.20PubMed Central. Variability in Global Prevalence of Interstitial Lung Disease These wide ranges reflect genuine differences in exposure patterns, genetics, diagnostic access, and study methodology.
Treatment for Pulmonary Interstitial Fibrosis
Treatment depends heavily on the underlying cause and type of interstitial fibrosis. The approach for idiopathic pulmonary fibrosis is quite different from the approach for autoimmune-related disease, even though the end result, scarring, looks similar under a microscope.
Antifibrotic Drugs
Two antifibrotic medications, pirfenidone and nintedanib, are the mainstays for idiopathic pulmonary fibrosis and have also shown benefit in other forms of progressive lung fibrosis. Nintedanib works by blocking several growth factor receptors, which prevents fibroblasts and myofibroblasts from ramping up production of scar tissue. Pirfenidone’s mechanism is less precisely understood but appears to combine anti-inflammatory and antifibrotic effects, slowing the growth of fibroblasts and their conversion into myofibroblasts.21PubMed Central. A Comparison of the Effectiveness of Nintedanib and Pirfenidone in Treating Idiopathic Pulmonary Fibrosis: A Systematic Review A systematic review and meta-analysis found that both drugs offer similar protection against the rate of lung function decline, and that their benefit holds whether the underlying fibrosis is idiopathic or related to another condition with progressive scarring.22PubMed Central. Efficacy of antifibrotic drugs, nintedanib and pirfenidone, in treatment of progressive pulmonary fibrosis in both idiopathic pulmonary fibrosis (IPF) and non-IPF: a systematic review and meta-analysis
Neither drug reverses existing scar tissue. They slow the disease down, buying time and preserving the lung function you still have. Side effects are a real consideration: gastrointestinal problems like diarrhea, nausea, and vomiting are common with both, and pirfenidone carries additional risks of sun sensitivity and skin rashes.23PubMed Central. Pirfenidone and Nintedanib in Pulmonary Fibrosis: Lights and Shadows
Immunosuppressive and Immunomodulatory Therapy
When interstitial fibrosis is driven by an autoimmune or inflammatory condition, tamping down the immune system is central to treatment. The agents most commonly used include corticosteroids, mycophenolate mofetil, azathioprine, methotrexate, cyclophosphamide, and rituximab. These are largely successful in managing autoimmune-related interstitial lung disease, though each carries its own side-effect profile and requires specific monitoring.24PubMed Central. Immunomodulatory treatment of interstitial lung disease One important caveat: large randomized controlled trials for many of these drugs in the context of autoimmune lung disease are still lacking, so treatment decisions rely heavily on clinical experience and smaller studies.25PubMed. Immunosuppressive therapy for autoimmune lung diseases Immunosuppression can actually be harmful in idiopathic pulmonary fibrosis, which is why distinguishing between the two is so important diagnostically.
Pulmonary Rehabilitation
Pulmonary rehabilitation, a structured program of exercise training, breathing techniques, and education, does not slow fibrosis itself but makes a meaningful difference in daily life. A real-world study comparing pulmonary rehabilitation outcomes in IPF patients and COPD patients found that both groups showed significantly improved breathlessness scores, walking distance, and quality-of-life measures after completing the program.26PubMed Central. Pulmonary Rehabilitation in Idiopathic Pulmonary Fibrosis and COPD A Propensity-Matched Real-World Study Separate research has shown significant reductions in fatigue and improvements in quality of life at both three and six months after beginning rehabilitation.27International Journal of Experimental Research and Review. Impact of Pulmonary Rehabilitation on Fatigue and Quality of Life in Patients of Interstitial Lung Disease
Lung Transplantation
For patients with advanced pulmonary fibrosis who have no absolute surgical contraindications, lung transplantation remains the only option that can genuinely restore lung function. Every patient diagnosed with IPF should ideally be referred to a transplant center early for assessment, because the disease can progress unpredictably.28PubMed Central. Lung Transplantation in Idiopathic Pulmonary Fibrosis That said, post-transplant survival in IPF patients tends to be somewhat lower than in recipients transplanted for conditions like cystic fibrosis or COPD, largely because pulmonary fibrosis patients tend to be older and have more accompanying health conditions at the time of surgery.
Complications That Make Fibrosis Harder to Live With
The scarring itself is not the only problem. As interstitial fibrosis progresses, it often brings complications that compound the burden. Pulmonary hypertension, or elevated blood pressure in the lung’s arteries, is strongly associated with decreased exercise capacity, more frequent hospitalizations, and higher mortality in patients with interstitial lung disease.29PubMed Central. Clinical significance of pulmonary hypertension in interstitial lung disease The stiffened, scarred lungs force the heart to work harder to push blood through them, and over time this extra strain can lead to right-sided heart failure.
From the patient’s perspective, the day-to-day symptom burden extends well beyond breathlessness. As the disease worsens, chronic cough and progressive shortness of breath typically lead to oxygen dependence. Depression, anxiety, and persistent fatigue are common and frequently underrecognized, adding to the overall decline in quality of life.30PubMed Central. The Role of Palliative Care in Reducing Symptoms and Improving Quality of Life for Patients with Idiopathic Pulmonary Fibrosis: A Review Palliative care, focused on symptom control and quality of life rather than cure, remains underutilized in pulmonary fibrosis compared with conditions like lung cancer, even though the symptom burden can be comparable. Surveys of pulmonary physicians have found that less morphine is prescribed for IPF breathlessness than for lung cancer breathlessness, and that clinicians themselves perceive palliative care for fibrosis patients as more difficult to deliver.31PubMed. Palliative Care for Idiopathic Pulmonary Fibrosis Patients: Pulmonary Physicians’ View
Emerging Therapies and Research Directions
Current antifibrotic drugs slow the process but do not stop or reverse it, which has fueled an active pipeline of experimental therapies targeting different parts of the fibrosis machinery. International guidelines for both idiopathic pulmonary fibrosis and progressive pulmonary fibrosis have explicitly called for novel treatments targeting the molecular pathways behind scar formation. Among the most promising areas are senolytics (drugs that clear out aged, malfunctioning cells that secrete pro-fibrotic signals), stem cell therapies, and inhibitors of specific signaling pathways including PDE4B, TGF-beta, the lysophosphatidic acid pathway, and several others.32PubMed Central. Most Promising Emerging Therapies for Pulmonary Fibrosis: Targeting Novel Pathways Many of these are still in early clinical trials, and it will be years before any reach routine clinical use. But the breadth of the research pipeline reflects a growing recognition that fibrosis is not one pathway but many, and that effective future treatment may involve combinations of drugs hitting different targets simultaneously, much like how cancer treatment has evolved.
For kidney and cardiac fibrosis, the therapeutic landscape is at an even earlier stage. Most anti-fibrotic research has focused on the lungs, and there is considerable interest in whether insights from pulmonary fibrosis could translate to other organs. The shared biology, myofibroblasts, excess collagen, and overlapping signaling molecules like TGF-beta, suggests that at least some drugs effective in the lung could find application elsewhere. Whether that hope materializes is one of the bigger open questions in fibrosis research.